Franco-Japanese pairing to promote Tenelia in China

Tianjin Tanabe Seiyaku, a subsidiary of Japanese drug major Mitsubishi Tanabe Pharma (TYO: 4508), has teamed up with French independent drugmaker Servier Laboratories, to promote the type 2 diabetes drug Tenelia (teneligliptin).

China has the world’s largest population of people with type 2 diabetes and the number of diabetics is expected to increase from the current 130 million.

The collaboration with Servier, which has around 700 medical representatives in China specializing in diabetes and has a track record in sales going back 40 years, is expected to lead to the rapid market penetration of Tenelia and to the maximization of its value.